Home News Cancer News Patients Favor Single-Port Robotic System for Uro-Oncology Surgery

Patients Favor Single-Port Robotic System for Uro-Oncology Surgery

Patients in the single-port versus multiport system group reported better cosmetic appearance, higher satisfaction with cosmetic appearance of surgical scar

MONDAY, Oct. 31, 2022 (HealthDay News) — For patients undergoing urologic oncology procedures, use of the da Vinci single-port (SP) robotic system is perceived favorably by patients compared with a multiport platform, according to a study published in the Nov. 1 issue of Urology Practice.

Luca A. Morgantini, M.D., from the University of Illinois at Chicago, and colleagues administered the Patient Scar Assessment Questionnaire to patients who underwent an SP or multiport platform (Xi) urological procedure (104 and 78 patients, respectively). Appearance, consciousness, satisfaction with appearance, and satisfaction with symptoms were assessed; higher scores represented worse outcomes.

The researchers found that the SP procedure recipients reported significantly better cosmetic scar appearance compared with the Xi procedure recipients (mean, 13.84 versus 15.28). Similarly, the SP cohort had significantly better consciousness of their surgical scar (mean, 8.80 versus 9.87) and higher satisfaction with the cosmetic appearance of their surgical scar compared with the Xi group (mean, 11.35 versus 12.54). Although the SP group attained lower scores on satisfaction with symptoms than the Xi group, the difference was not significant (mean, 6.58 versus 6.74).

“Our findings demonstrate a correlative improvement in patient-reported outcomes related to scar aesthetics, scar-related self-consciousness, and satisfaction with scar aesthetics in patients receiving SP urologic oncology procedures compared to those receiving multi-port urologic oncology procedures,” the authors write.

One author disclosed financial ties to Intuitive, the manufacturer of the da Vinci single-port robotic system.

Abstract/Full Text

Copyright © 2022 HealthDay. All rights reserved.